<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793112</url>
  </required_header>
  <id_info>
    <org_study_id>2022P002752</org_study_id>
    <nct_id>NCT05793112</nct_id>
  </id_info>
  <brief_title>INF108F in Infants With Food Protein Induced Proctocolitis</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Restoring Gut Health With INF108F in Infants With Food Protein Induced Allergic Proctocolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, randomized, double-blind, placebo-controlled trail evaluating INF108F in&#xD;
      breastfed infants with FPIAP&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled trial with two arms&#xD;
      evaluating IBF108F in breastfed infants with FPIAP. Assessments will be conducted over a&#xD;
      4-week study period with assessment of blood in stool, infant stooling, sleep, feeding, and&#xD;
      growth. Safety will be evaluated through collection adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2023</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes to gut microbiome composition</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Changes to the gut microbiome composition in infants with FPIAP over a 4-week period. We will analyze the 16S rRNA of the gut microbiome as well as the short-gun sequencing of metagenomic species of the gut microbiome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes to clinical symptoms of FPIAP</measure>
    <time_frame>Baseline to day 28</time_frame>
    <description>Changes to clinical symptoms of FPIAP, specifically we will collect information using questionnaire about infants' GER symptoms, feeding, sleep and stool frequency and consistency. The severity of GER will be quantified using the Infant GER Questionnaire (I-GERQ), with numeric scores, the higher score means more severe GER, the maximum score is 25, scores &gt;7 provide 74% specificity and 94% sensitivity for diagnosing GERD. The sleep will be captured using Infant Sleep Questionnaire, with 0-10 scales, 0 means worst sleep and 10 means excellent sleep for quantify the quality of infant's night sleep.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infant Development</condition>
  <condition>Gut Microbiome</condition>
  <condition>Food Protein Induced Allergic Proctocolitis</condition>
  <arm_group>
    <arm_group_label>INF108F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INF108F</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INF108F probiotic</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>INF108F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral suspension</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants, male or female, of all ethnic/racial groups, with a gestational period of 37&#xD;
             to 42 weeks&#xD;
&#xD;
          -  Infants aged 1 - 60 days old with a documented FPIAP with either gross blood or&#xD;
             microscopic blood in without other possible causes&#xD;
&#xD;
          -  Infants must be exclusively breastfed or at least half of oral intake is from breast&#xD;
             feeding or from expressed breast milk&#xD;
&#xD;
          -  A willing parent or legal guardian will sign the consent form either electronically or&#xD;
             with a wet ink signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants born earlier than 37 weeks of gestation&#xD;
&#xD;
          -  Infants who are exclusively formula-fed or less than half of oral intake is from&#xD;
             breastfeeding or from expressed breast milk at the time of enrollment&#xD;
&#xD;
          -  Infants born with medical complications (i.e., neurological, cerebral palsy, confirmed&#xD;
             food allergies)&#xD;
&#xD;
          -  Diagnosis of other severe or complicating medical problems, including autoimmune or&#xD;
             chronic immune inflammatory conditions, gastrointestinal inflammatory conditions, or&#xD;
             renal insufficiency&#xD;
&#xD;
          -  History of abdominal surgery or congenital abnormalities of the GI track, the&#xD;
             cardiovascular system, the pulmonary system or the renal system&#xD;
&#xD;
          -  Antibiotic use (oral or systemic) within 7 days prior to enrollment&#xD;
&#xD;
          -  Mother's intent to feed non-study probiotics or solid food to their infant at any time&#xD;
             during the study&#xD;
&#xD;
          -  Mothers with substance use disorder (SUD) or on Nicotine replacement therapy (NRT)&#xD;
&#xD;
          -  Infants who have consumed any B. infantis-containing probiotics since birth&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arsal Khan, BA</last_name>
    <phone>617-643-8298</phone>
    <email>akhan51@mgh.harvard.edu</email>
  </overall_contact>
  <results_reference>
    <citation>Martin VM, Virkud YV, Seay H, Hickey A, Ndahayo R, Rosow R, Southwick C, Elkort M, Gupta B, Kramer E, Pronchick T, Reuter S, Keet C, Su KW, Shreffler WG, Yuan Q. Prospective Assessment of Pediatrician-Diagnosed Food Protein-Induced Allergic Proctocolitis by Gross or Occult Blood. J Allergy Clin Immunol Pract. 2020 May;8(5):1692-1699.e1. doi: 10.1016/j.jaip.2019.12.029. Epub 2020 Jan 7.</citation>
    <PMID>31917366</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin VM, Virkud YV, Phadke NA, Su KW, Seay H, Atkins MR, Keet C, Shreffler WG, Yuan Q. Increased IgE-Mediated Food Allergy With Food Protein-Induced Allergic Proctocolitis. Pediatrics. 2020 Sep;146(3):e20200202. doi: 10.1542/peds.2020-0202. No abstract available.</citation>
    <PMID>32855350</PMID>
  </results_reference>
  <results_reference>
    <citation>Radano MC, Yuan Q, Katz A, Fleming JT, Kubala S, Shreffler W, Keet CA. Cesarean section and antibiotic use found to be associated with eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2014 Jul-Aug;2(4):475-477.e1. doi: 10.1016/j.jaip.2014.02.018. Epub 2014 May 1. No abstract available.</citation>
    <PMID>25017541</PMID>
  </results_reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Qian Yuan, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctocolitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

